MX2017003426A - Vectores virales adeno-asociados para tratar glaucoma de miocilina (myoc). - Google Patents
Vectores virales adeno-asociados para tratar glaucoma de miocilina (myoc).Info
- Publication number
- MX2017003426A MX2017003426A MX2017003426A MX2017003426A MX2017003426A MX 2017003426 A MX2017003426 A MX 2017003426A MX 2017003426 A MX2017003426 A MX 2017003426A MX 2017003426 A MX2017003426 A MX 2017003426A MX 2017003426 A MX2017003426 A MX 2017003426A
- Authority
- MX
- Mexico
- Prior art keywords
- myoc
- spondin
- adeno
- glaucoma
- myocilin
- Prior art date
Links
- 102100029839 Myocilin Human genes 0.000 title abstract 6
- 101710196550 Myocilin Proteins 0.000 title abstract 6
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- 101150104791 MYOC gene Proteins 0.000 title 1
- 239000013603 viral vector Substances 0.000 title 1
- 101000825954 Homo sapiens R-spondin-1 Proteins 0.000 abstract 3
- 101000825949 Homo sapiens R-spondin-2 Proteins 0.000 abstract 3
- 101000825960 Homo sapiens R-spondin-3 Proteins 0.000 abstract 3
- 101000825962 Homo sapiens R-spondin-4 Proteins 0.000 abstract 3
- 102100022762 R-spondin-1 Human genes 0.000 abstract 3
- 102100022763 R-spondin-2 Human genes 0.000 abstract 3
- 102100022766 R-spondin-3 Human genes 0.000 abstract 3
- 102100022759 R-spondin-4 Human genes 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 3
- 230000003612 virological effect Effects 0.000 abstract 3
- 108091030071 RNAI Proteins 0.000 abstract 2
- 230000009368 gene silencing by RNA Effects 0.000 abstract 2
- 239000013607 AAV vector Substances 0.000 abstract 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 abstract 1
- 210000001585 trabecular meshwork Anatomy 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051299P | 2014-09-16 | 2014-09-16 | |
| PCT/US2015/050515 WO2016044478A1 (en) | 2014-09-16 | 2015-09-16 | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017003426A true MX2017003426A (es) | 2017-07-28 |
Family
ID=58640637
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003426A MX2017003426A (es) | 2014-09-16 | 2015-09-16 | Vectores virales adeno-asociados para tratar glaucoma de miocilina (myoc). |
| MX2023005998A MX2023005998A (es) | 2014-09-16 | 2017-03-15 | Vectores virales adeno-asociados para tratar glaucoma de miocilina (myoc). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005998A MX2023005998A (es) | 2014-09-16 | 2017-03-15 | Vectores virales adeno-asociados para tratar glaucoma de miocilina (myoc). |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10821193B2 (enExample) |
| EP (1) | EP3194601B1 (enExample) |
| JP (2) | JP6673923B2 (enExample) |
| KR (2) | KR20230172610A (enExample) |
| CN (2) | CN107001436B (enExample) |
| AU (2) | AU2015317756B2 (enExample) |
| BR (1) | BR112017005235B1 (enExample) |
| IL (1) | IL251178B (enExample) |
| MX (2) | MX2017003426A (enExample) |
| RU (2) | RU2718047C2 (enExample) |
| SG (3) | SG11201702055PA (enExample) |
| ZA (1) | ZA201701881B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201702055PA (en) | 2014-09-16 | 2017-04-27 | Genzyme Corp | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma |
| EP3751000B1 (en) * | 2018-02-07 | 2024-11-27 | Nippon Medical School Foundation | Improved adeno-associated virus vector |
| WO2019165241A1 (en) * | 2018-02-22 | 2019-08-29 | University Of South Florida | Grp94 inhibitors to treat steroid-induced ocular hypertensions and glaucomas |
| WO2020176747A1 (en) | 2019-02-28 | 2020-09-03 | Regeneron Pharmaceuticals, Inc. | Adeno-associated virus vectors for the delivery of therapeutics |
| WO2022120080A1 (en) * | 2020-12-03 | 2022-06-09 | University Of Massachusetts | Development of novel gene therapeutics for fibrodysplasia ossificans progressiva |
| CN113032010B (zh) * | 2021-03-12 | 2022-09-20 | 歌尔科技有限公司 | 命令的传输控制方法、终端及计算机可读存储介质 |
| EP4363587A4 (en) * | 2021-06-28 | 2025-08-06 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION |
| WO2023114446A2 (en) * | 2021-12-16 | 2023-06-22 | Peter Koulen | A machine learning-based framework using electroretinography for detecting early-stage glaucoma |
| CN117343152B (zh) * | 2023-04-18 | 2024-06-04 | 上海本导基因技术有限公司 | 一种用于治疗青光眼疾病的慢病毒样颗粒 |
| CN118546217B (zh) * | 2024-07-25 | 2024-10-29 | 广州译码基因科技有限公司 | 靶向小梁网、角膜缘及rpe的aav衣壳蛋白及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050130145A1 (en) | 2001-10-03 | 2005-06-16 | Henry Yue | Secreted proteins |
| GB0403600D0 (en) * | 2004-02-18 | 2004-03-24 | Trinity College Dublin | Methods and reagents for treating disease |
| WO2005117938A2 (en) * | 2004-04-13 | 2005-12-15 | Regents Of The University Of Minnesota | Methods of treating ocular conditions |
| WO2008075796A1 (ja) * | 2006-12-21 | 2008-06-26 | Kyowa Hakko Kirin Co., Ltd. | 血球回復促進剤 |
| JP2010540564A (ja) * | 2007-10-01 | 2010-12-24 | アルコン リサーチ， リミテッド | 自己相補的なａａｖが媒介する眼の障害を処置または予防するための干渉ｒｎａ分子の送達 |
| GB201106395D0 (en) * | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
| MX349138B (es) | 2011-04-22 | 2017-07-13 | Univ California | Variones de virus adeno-asociados con capside variante y sus metodos de uso. |
| EP2554662A1 (en) * | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
| SG11201404703WA (en) * | 2012-02-11 | 2014-09-26 | Genentech Inc | R-spondin translocations and methods using the same |
| WO2013170078A1 (en) * | 2012-05-09 | 2013-11-14 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| SG11201702055PA (en) | 2014-09-16 | 2017-04-27 | Genzyme Corp | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma |
-
2015
- 2015-09-16 SG SG11201702055PA patent/SG11201702055PA/en unknown
- 2015-09-16 US US15/511,595 patent/US10821193B2/en active Active
- 2015-09-16 BR BR112017005235-0A patent/BR112017005235B1/pt active IP Right Grant
- 2015-09-16 RU RU2017112972A patent/RU2718047C2/ru active
- 2015-09-16 KR KR1020237042363A patent/KR20230172610A/ko active Pending
- 2015-09-16 RU RU2020111038A patent/RU2746991C2/ru active
- 2015-09-16 JP JP2017534525A patent/JP6673923B2/ja active Active
- 2015-09-16 EP EP15772133.3A patent/EP3194601B1/en active Active
- 2015-09-16 SG SG10201902285SA patent/SG10201902285SA/en unknown
- 2015-09-16 AU AU2015317756A patent/AU2015317756B2/en active Active
- 2015-09-16 KR KR1020177010012A patent/KR102612871B1/ko active Active
- 2015-09-16 IL IL251178A patent/IL251178B/en unknown
- 2015-09-16 CN CN201580061882.5A patent/CN107001436B/zh active Active
- 2015-09-16 MX MX2017003426A patent/MX2017003426A/es unknown
- 2015-09-16 SG SG10201913430VA patent/SG10201913430VA/en unknown
- 2015-09-16 CN CN202211533202.3A patent/CN116585492A/zh active Pending
-
2017
- 2017-03-15 MX MX2023005998A patent/MX2023005998A/es unknown
- 2017-03-16 ZA ZA2017/01881A patent/ZA201701881B/en unknown
-
2020
- 2020-03-04 JP JP2020036344A patent/JP7097398B2/ja active Active
-
2022
- 2022-04-12 AU AU2022202413A patent/AU2022202413A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201701881B (en) | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma | |
| MX2019013172A (es) | Composiciones y metodos para tratar la enfermedad de huntington. | |
| MX2022012490A (es) | Vectores de aav para la terapia genica de la retina y el snc. | |
| MX394909B (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos | |
| DOP2016000237A (es) | Terapia genica para la retinitis pigmentaria | |
| MX2019013072A (es) | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. | |
| MX2023013435A (es) | Composiciones y metodos para expresar otoferlina. | |
| PH12017500692A1 (en) | Antibody molecules to pd-l1 and uses thereof | |
| EA201790434A1 (ru) | Модуляторы каналов | |
| MX2017005977A (es) | Anticuerpos biespecificos y metodos de uso en oftalmologia. | |
| PH12017500032B1 (en) | Improved aã protofibril binding antibodies | |
| MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
| WO2016089886A3 (en) | Methods for treating dry eye disease by administering an il-6r antagonist | |
| MX2017004986A (es) | Anticuerpos dirigidos a angiopoyetina-1 y angiopoyetina-2 para terapias oculares. | |
| HK1241924A1 (en) | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma | |
| NZ734845A (en) | Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease | |
| TN2016000460A1 (en) | Aav vectors for retinal and cns gene therapy. | |
| MY173606A (en) | Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease |